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This Month in the Journal
This month we feature a series of reviews on the genetics
of cardiovascular development and disease. Rudic and
Sessa (p. 673) discuss the physiological control of vas-
cular diameter in response to changes in blood flow. This
vascular remodeling goes awry in hypertension and ath-
erosclerosis, which appears to be regulated by endothe-
lial nitric oxide synthase. Towbin et al. (p. 678) review
cardiovascular development and survey various disor-
ders of vascular morphogenesis, including a number of
hereditary defects for which the underlying genes are
now available for study. Xiao and Benjamin (p. 685)
discuss the significance of stress-response proteins in car-
diac health. They indicate that heat-shock proteins may
be important tools for reducing damage in ischemic tis-
sues. Furthermore, endogenous proteins of this kind,
specifically aB-crystallin, are required in order to main-
tain the normal function of cardiac and skeletal mus-
cle. Finally, Ring and Cho (p. 691) review the signal-
transduction pathways for transforming growth factor
(TGF)–b and its relatives. This superfamily of cytokines
shapes the development of the vasculature as well as
many other tissues and organs, and TGF-b–signaling
mediators have been implicated in hereditary hemor-
rhagic telangiectasia. TGF-b signaling has been exten-
sively studied in the early development of the frog, and
Ring and Cho discuss work in this system that begins
to explain how this ubiquitous biochemical pathway can
induce such a diversity of specific biological responses.
Bicistronic MPT-Synthase Transcript, by Stallmeyer et
al. (p. 698); Molybdenum Cofactor Deficiency Type B,
by Reiss et al. (p. 706)
Molybdopterin, an essential cofactor that is found in all
eukaryotic molybdoenzymes, is synthesized in two steps
catalyzed by molybdenum cofactor synthases (MOCS)
1 and 2. Deficiency of either of these heterodimeric pro-
teins can lead to molybdenum-cofactor deficiency, a rare
but lethal inborn error. The two subunits of MOCS1 are
encoded by a single mRNA species, which carries two
discontinuous open reading frames (ORFs). Stallmeyer
et al. show that, remarkably, the MOCS2 mRNA is also
bicistronic. This message contains a short 5′ ORF, which
encodes the 10-kD subunit of MOCS2, and an overlap-
ping 3′ ORF, which encodes the 21-kD subunit. Ex-
pression of the downstream ORF seems to depend on
leaky ribosomal scanning of the mRNA, rather than on
internal translational initiation, since an inhibitor of 5′
mRNA end recognition suppresses the in vitro transla-
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tion of both subunits equally. This leaky scanning mech-
anism has been found in some viral transcripts but is
quite rare in mammalian mRNAs. Reiss et al. have also
identified five MOCS2 mutations among seven homo-
zygous or compound heterozygous individuals with mo-
lybdenum-cofactor deficiency.
LEFTY and Left-Right Axis Malformations, by
Kosaki et al. (p. 712)
Several vertebrate genes that affect the development of
left-right asymmetries have been characterized in recent
years, and a few familial or sporadic human cases of
abnormal laterality are now beginning to be understood.
Kosaki and colleagues have cloned two tandemly re-
peated genes, LEFTY-A and LEFTY-B, homologues of
Lefty-1 and Lefty-2, which underlie laterality defects in
the mouse. LEFTY-A encodes a previously identified
member of the TGF-b superfamily, TGF-b4, and point
mutations in this gene appear to account for the mal-
formations seen in 2 situs individuals, among 126 such
cases examined. The detailed cardiac and pulmonary
features of these individuals generally match the phe-
notypes seen in lefty-1/ mice. The mode of transmis-
sion of LEFTY-related situs defects is complex in both
species. Indeed, the probands reported by Kosaki et al.
are heterozygotes who had inherited a mutant LEFTY-
A allele from an unaffected parent; background geno-
type and stochastic effects probably both influence the
laterality phenotype in homozygotes and heterozygous
carriers. For more on cardiac laterality and other mal-
formations, see Towbin et al. (p. 678); for more on TGF-
b signaling, see Ring and Cho (p. 691).
Cyclic Ichthyosis with Epidermolytic Hyperkeratosis,
by Sybert et al. (p. 732)
Sybert and coworkers report a novel mutation in the
gene for keratin-1 (KRT1) that causes a distinctive skin
disorder, which they term “cyclic ichthyosis with epi-
dermolytic hyperkeratosis.” Presentation of this condi-
tion only partly overlaps with bullous congenital ichthy-
osiform erythroderma, a well-studied disorder in which
both of the suprabasal cell keratins, K1 and K10, have
been implicated. Sybert et al. noted that individuals from
two unrelated families, who were examined 10 years
apart, both experienced explosive bouts of erythematous
plaques that covered much of their bodies. The pres-
ence of cytokeratin aggregates in suprabasal skin cells
prompted them to sequence these patients’ KRT1 and
KRT10 genes, and they report here that both families
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with this unusual disorder carry missense mutations that
affect the identical codon of KRT1.
Mutations in MRP2/cMOAT Gene in DJS, by
Toh et al. (p. 739)
ATP-binding–cassette (ABC) proteins first came to at-
tention with the identification of the multidrug-resis-
tance transporter (MDR1). This family of versatile trans-
membrane-transport proteins also includes the cystic
fibrosis transmembrane-conductance regulator (CFTR)
and the canilicular multispecific organic anion trans-
porter (cMOAT). cMOAT is expressed on the apical
surface of hepatocytes and appears to shuttle glutathi-
one-conjugated bilirubin into the bile, for excretion. Toh
et al. recently implicated cMOAT in Dubin-Johnson syn-
drome (DJS), an autosomal recessive condition in which
bilirubin and various drugs accumulate as glutathione
conjugates in the bloodstream. These authors now pre-
sent the exon structure of this gene, and they identify
four probable disease alleles, one of which was known
from their previous study. One missense mutation is
identical to a mutation found at the corresponding site
in a disease allele of CFTR.
Localization of a Prostate-Brain Cancer–Susceptibility
Locus, by Gibbs et al. (p. 776)
As Gibbs and colleagues have suggested in the past, the
contradictory linkage findings that have bedeviled the
search for prostate cancer genes could be explained by
locus heterogeneity and subtle differences in ascertain-
ment in different studies. Now, these authors have at-
tempted to turn this heterogeneity to advantage by fo-
cusing on a specific subset of probands with prostate
cancer—namely, those who have a family history of ma-
lignant brain tumors. Initial evidence linked prostate
cancer to 1p36, a region that is commonly deleted in
brain tumors but that has not been reported previously
in prostate cancer studies. Among 141 prostate cancer
families, Gibbs et al. found linkage to markers in this
region in only the 12 families with a history of malignant
brain tumors and of early-manifesting prostate cancer.
The suggestion of a prostate and brain cancer gene is
consistent with epidemiological work that suggests that
tumors in the CNS are increased in frequency in prostate
cancer families.
Homozygous Parent TDT Analysis of IDDM1, by
Lie et al. (p. 793)
The portion of 6p that carries the human leukocyte an-
tigen (HLA) major histocompatibility loci has been im-
plicated in numerous autoimmune disorders, but this
region often confounds detailed genetic analysis, perhaps
because it is relatively rich in genes and is subject to
strong transmission disequilibrium. Insulin-dependent
diabetes mellitis (IDDM) is among the best studied of
these disorders, and specific HLA haplotypes have been
defined that promote the disease in humans and mice.
Still, it has been difficult to untangle the effects at these
loci from those of other, potentially tightly linked genes.
Lie et al. have devised a statistical approach, the so-
called homozygous parent TDT, that allows them to de-
tect the latter effects. Starting with samples from three
large northern European IDDM studies, Lie et al. se-
lected 225 families in which one or both parents were
homozygous for an HLA haplotype, and they applied
the TDT in order to find alleles at surrounding loci that
are preferentially transmitted to affected children. They
show that one or more genes, probably located several
megabases telomeric to the HLA region, promote
IDDM, at least in the context of particular HLA hap-
lotypes. The precise localization of these genes remains
a challenge, but a mouse IDDM-related gene, which has
been identified in a syntenic region, may prove more
tractable.
The Duty to Recontact, by Fitzpatrick et al. (p. 852)
Individuals and families referred for genetic diagnosis or
counseling clearly deserve the most accurate information
available at the time of their visit, but what should they
expect once they have left the clinic? Do advances in
diagnosis, prognosis, or treatment of genetic disorders
obligate genetics service providers to reestablish contact
with all their former patients? Fitzpatrick and coworkers
have surveyed 252 North American members of the
American Society of Human Genetics on a number of
such questions, and they report here that there is little
consensus on the notion of a “duty to recontact.”
Among respondents who see patients, a clear majority
indicated that they had, on some occasions, recontacted
one or more individuals with regard to recent advances,
but considerably fewer respondents felt that recontact
should be the standard of care. The demands on time
and resources seem to cause the greatest concern. An
alternative approach that might address these problems
would be to work through referring physicians. This
possibility was not explicitly considered in the ques-
tionnaire, but Fitzpatrick et al. conclude by suggesting
several such measures that might increase patient or phy-
sician involvement and help provide up-to-date infor-
mation to those at risk of carrying or transmitting a
hereditary disorder.
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